Plasma ADMA concentrations associate with aerobic fitness in postmenopausal women

Life Sciences

Volumn 108, Issue 1, 2014, Pages 30-33

  Tanahashi, Koichiro ^a   Akazawa, Nobuhiko ^a   Miyaki, Asako ^a   Choi, Youngju ^a   Ra, Song Gyu ^a   Matsubara, Tomoko ^a   Kumagai, Hiroshi ^a   Oikawa, Satoshi ^a   Miyauchi, Takashi ^a   Maeda, Seiji ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

ADMA; Aerobic exercise capacity; Aging; Cardiovascular disease; Endothelin

Indexed keywords

N(G),N(G) DIMETHYLARGININE; OXYGEN;

ADULT; AEROBIC FITNESS; AGED; BLOOD LEVEL; BLOOD PRESSURE; CONFERENCE PAPER; FEMALE; FITNESS; HEART RATE; HUMAN; NORMAL HUMAN; OXYGEN CONSUMPTION; POSTMENOPAUSE;

ADMA; AEROBIC EXERCISE CAPACITY; AGING; CARDIOVASCULAR DISEASE; ENDOTHELIN;

AGED; ARGININE; EXERCISE; FEMALE; HUMANS; MIDDLE AGED; OXYGEN CONSUMPTION; PHYSICAL FITNESS; POSTMENOPAUSE;

EID: 84903735515     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.05.003     Document Type: Conference Paper

References (32)

1. V. Achan, M. Broadhead, M. Malaki, G. Whitley, J. Leiper, and R. MacAllister et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase Arterioscler Thromb Vasc Biol 23 2003 1455 1459
2. C.C. Allain, L.S. Poon, C.S. Chan, W. Richmond, and P.C. Fu Enzymatic determination of total serum cholesterol Clin Chem 20 1974 470 475
3. J. Bełtowski, and A. Kedra Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy Pharmacol Rep 58 2006 159 178
4. R.H. Böger, S.M. Bode-Böger, A. Szuba, P.S. Tsao, J.R. Chan, and O. Tangphao et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia Circulation 98 1998 1842 1847
5. R.H. Böger, L.M. Sullivan, E. Schwedhelm, T.J. Wang, R. Maas, and E.J. Benjamin et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community Circulation 119 2009 1592 1600
6. J.P. Cooke Asymmetrical dimethylarginine: the Uber marker? Circulation 109 2004 1813 1818
7. H.M. Eid, H. Arnesen, E.M. Hjerkinn, T. Lyberg, and I. Seljeflot Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine Metabolism 53 2004 1574 1579
8. E. Fabian, M. Bogner, and I. Elmadfa Age-related modification of antioxidant enzyme activities in relation to cardiovascular risk factors Eur J Clin Invest 42 2012 42 48
9. 2 +/dextran sulfate in its enzymic measurement Clin Chem 24 1978 931 933
10. S.M. Fox, J.P. Naughton, and W.L. Haskell Physical activity and the prevention of coronary heart disease Ann Clin Res 3 1971 404 432
11. K. Furuki, H. Adachi, M. Enomoto, M. Otsuka, A. Fukami, and S. Kumagae et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography Hypertens Res 31 2008 1185 1189
12. H. Hanssen, T. Nickel, V. Drexel, G. Hertel, I. Emslander, and Z. Sisic et al. Exercise-induced alterations of retinal vessel diameters and cardiovascular risk reduction in obesity Atherosclerosis 216 2011 433 439
13. K. Hasegawa, S. Wakino, S. Tatematsu, K. Yoshioka, K. Homma, and N. Sugano et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2 Circ Res 101 2007 e2 e10
14. S. Hawkins, and R. Wiswell Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training Sports Med 33 2003 877 888
15. J.T. Kielstein, S.M. Bode-Böger, J.C. Frölich, E. Ritz, H. Haller, and D. Fliser Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects Circulation 107 2003 1891 1895
16. M. Kohlmeier Direct enzymic measurement of glycerides in serum and in lipoprotein fractions Clin Chem 32 1986 63 66
17. J. Leiper, and P. Vallance Biological significance of endogenous methylarginines that inhibit nitric oxide synthases Cardiovasc Res 43 1999 542 548
18. T. Leong, D. Zylberstein, I. Graham, L. Lissner, D. Ward, and J. Fogarty et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg Arterioscler Thromb Vasc Biol 28 2008 961 967
19. D. Malatesta, D. Simar, Y. Dauvilliers, R. Candau, H. Ben Saad, and C. Préfaut et al. Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds Pflugers Arch 447 2004 915 921
20. R.G. McMurray, B.E. Ainsworth, J.S. Harrell, T.R. Griggs, and O.D. Williams Is physical activity or aerobic power more influential on reducing cardiovascular disease risk factors? Med Sci Sports Exerc 30 1998 1521 1529
21. H. Miyazaki, H. Matsuoka, J.P. Cooke, M. Usui, S. Ueda, and S. Okuda et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis Circulation 99 1999 1141 1146
22. V. Pialoux, A.D. Brown, R. Leigh, C.M. Friedenreich, and M.J. Poulin Effect of cardiorespiratory fitness on vascular regulation and oxidative stress in postmenopausal women Hypertension 54 2009 1014 1020
23. F. Schulze, R. Maas, R. Freese, E. Schwedhelm, E. Silberhorn, and R.H. Böger Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects Eur J Clin Invest 35 2005 622 626
24. M.W. Slein d-Glucose: determination with hexokinase and glucose-6-phosphate dehydrogenase H.U. Bergmeyer, Methods of enzymatic analysis 1963 Academic Press New York, N.Y., USA 117
25. K. Sydow, and T. Münzel ADMA and oxidative stress Atheroscler Suppl 4 2003 41 51
26. K. Sydow, C.E. Mondon, and J.P. Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vasc Med 10 2005 S35 S43
27. H. Tanaka, F.A. Dinenno, K.D. Monahan, C.M. Clevenger, C.A. DeSouza, and D.R. Seals Aging, habitual exercise, and dynamic arterial compliance Circulation 102 2000 1270 1275
28. P.D. Thompson, D. Buchner, I.L. Pina, G.J. Balady, M.A. Williams, and B.H. Marcus et al. American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention; American Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation 107 2003 3109 3116
29. M. Usui, H. Matsuoka, H. Miyazaki, S. Ueda, S. Okuda, and T. Imaizumi Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure Life Sci 62 1998 2425 2430
30. V.P. Valkonen, H. Päivä, J.T. Salonen, T.A. Lakka, T. Lehtimäki, and J. Laakso et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine Lancet 358 2001 2127 2128
31. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure Lancet 339 1992 572 575
32. S. Yamashita, M. Nakamura, H. Koizumi, H. Oku, J.C. Sandoval, and K. Tsubakio-Yamamoto et al. Evaluation of a homogeneous assay for measuring LDL-cholesterol in hyperlipidemic serum specimens J Atheroscler Thromb 15 2008 82 86